Literature DB >> 11161859

The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma.

E P Toy1, J T Chambers, B M Kacinski, M B Flick, S K Chambers.   

Abstract

OBJECTIVE: We have previously shown that the macrophage colony-stimulating factor receptor (CSF-1R) and its ligand, CSF-1, together predict poor prognosis in epithelial ovarian carcinoma. The activated or phosphorylated form of CSF-1R (CSF-1Rphos) has been associated with enhanced invasive and metastatic potential. Our goal is to correlate CSF-1Rphos with known prognostic factors and to determine its role in predicting outcome in advanced ovarian cancer.
METHODS: One hundred forty-two primary and forty-seven metastatic epithelial ovarian tumors from 98 patients were immunohistochemically stained using antibodies PY809 and PY723 against their respective tyrosine residues associated with local invasiveness and metastasis. chi2 analysis was used to correlate CSF-1Rphos staining and previously studied prognosticators within each group. Kaplan-Meier curves of survival were comparedusing the log-rank test with significance of P < 0.05.
RESULTS: Forty-seven and nine-tenths percent (68/142) of primary tumors and forty-eight and nine-tenths percent (23/47) of metastatic tumors stained positive for PY809 and PY723, respectively. The PY809+ group was strongly associated with CSF-1R (P = 0.015) as was the PY723+ group (P = 0.025) in its respective subset. CSF-1Rphos by itself was not a predictor of survival or disease-free interval (DFI) in either the primary or metastatic group. However, when combined with CSF-1R in the metastatic group, the two together predicted worse survival (P = 0.007) and decreased DFI (P = 0.011).
CONCLUSIONS: Phosphorylated tyrosine kinase receptors are detectable in a significant number of ovarian tumors. Staining strongly correlates with CSF-1R. PY723+ metastases coexpressing CSF-1R portend a highly significant decrease in survival and increased risk of recurrence which may serve to identify high-risk ovarian cancer patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11161859     DOI: 10.1006/gyno.2000.6070

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  24 in total

Review 1.  The mammalian ovary from genesis to revelation.

Authors:  Mark A Edson; Ankur K Nagaraja; Martin M Matzuk
Journal:  Endocr Rev       Date:  2009-09-23       Impact factor: 19.871

2.  Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence.

Authors:  Christine Gruessner; Angelika Gruessner; Katherine Glaser; Nisreen AbuShahin; Yi Zhou; Cynthia Laughren; Heather Wright; Samantha Pinkerton; Xiaofang Yi; Jha'nae Stoffer; Masoud Azodi; Wenxin Zheng; Setsuko K Chambers
Journal:  Cancer Prev Res (Phila)       Date:  2014-06-20

3.  Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.

Authors:  James G Conway; Brad McDonald; Janet Parham; Barry Keith; David W Rusnak; Eva Shaw; Marilyn Jansen; Peiyuan Lin; Alan Payne; Renae M Crosby; Jennifer H Johnson; Lloyd Frick; Min-Hwa Jasmine Lin; Scott Depee; Sarva Tadepalli; Bart Votta; Ian James; Karen Fuller; Timothy J Chambers; Frederick C Kull; Stanley D Chamberlain; Jeff T Hutchins
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-25       Impact factor: 11.205

4.  Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colony-stimulating factor.

Authors:  Eugene P Toy; Masoud Azodi; Nancy L Folk; Christina M Zito; Caroline J Zeiss; Setsuko K Chambers
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

Review 5.  Role of CSF-1 in progression of epithelial ovarian cancer.

Authors:  Setsuko K Chambers
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

6.  Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate.

Authors:  Joan Manel Gasent Blesa; Enrique Grande Pulido; Juan Laforga Canales; Vicente Alberola Candel
Journal:  Case Rep Oncol       Date:  2009-12-11

7.  Profiling Y561-dependent and -independent substrates of CSF-1R in epithelial cells.

Authors:  Melodie L Knowlton; Laura M Selfors; Carolyn N Wrobel; Ting-Lei Gu; Bryan A Ballif; Steven P Gygi; Roberto Polakiewicz; Joan S Brugge
Journal:  PLoS One       Date:  2010-10-26       Impact factor: 3.240

8.  The multifunctional protein glyceraldehyde-3-phosphate dehydrogenase is both regulated and controls colony-stimulating factor-1 messenger RNA stability in ovarian cancer.

Authors:  Yi Zhou; Xiaofang Yi; Jha'nae B Stoffer; Nathalie Bonafe; Maureen Gilmore-Hebert; Jessica McAlpine; Setsuko K Chambers
Journal:  Mol Cancer Res       Date:  2008-08       Impact factor: 5.852

Review 9.  Mouse models for radiation-induced cancers.

Authors:  Leena Rivina; Michael J Davoren; Robert H Schiestl
Journal:  Mutagenesis       Date:  2016-05-21       Impact factor: 3.000

10.  Macrophage density and macrophage colony-stimulating factor expression predict the postoperative prognosis in patients with intrahepatic cholangiocarcinoma.

Authors:  Kosuke Oishi; Takanori Sakaguchi; Satoshi Baba; Shohachi Suzuki; Hiroyuki Konno
Journal:  Surg Today       Date:  2014-07-23       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.